Cereno Scientific announces a repurchase of warrants from European High Growth Opportunities Securitization Fund

Cereno Scientific (XSTAT: CRNO B) (“Cereno” or the “Company”) today announced that the Company has entered into an agreement with European High Growth Opportunities Securitization Fund where the warrants which according to the Company’s press release on December 7, 2021, were to be used for subscription to new shares will be repurchased. The warrants will be repurchased at a cost of MSEK 4.5.

European High Growth Opportunities Securitization Fund notified Cereno on December 7, 2021, regarding the exercise of 1,105,262 warrants which had right to 1,440,156 class B shares in the Company (the “Warrants”). The parties have now reached an agreement where these Warrants will be repurchased by Cereno at a cost of MSEK 4.5.

“Given the successful financing with TO1 in September, Cereno has a good financial position over the coming period. This transaction where the warrants that were to be used for subscription to new shares will be repurchased is deemed to be in the Company’s and the current shareholders best short and long-term interest,” says Sten R. Sörensen, CEO at Cereno Scientific.

The repurchased Warrants will become void and no new shares will be issued by the Company, meaning that the increase in the share capital announced on December 7, 2021 will not be completed. Cereno’s total share capital will continue to amount to SEK 10,526,178.2 divided into 105,261,782 shares of which 722,248 shares of series A and 104,539,534 shares of series B.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

This information is information that Cereno Scientific AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CET on December 15, 2021.

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.